After another record quarter, Germany’s Merck expects a COVID-19 windfall of €1 billion in 2021, the bulk of which coming from its Process Solutions unit. The German biopharma giant reported double-digit growth across all its segments in the second quarter 2021, but highlighted significant contributions from its ‘Big 3’: its Healthcare pipeline, Process Solutions, and Semiconductor Solutions units. The Process Solutions business, which falls under its Life Science business MilliporeSigma and offers biopharmaceutical products and services, pulled in €1.15 billion…